z-logo
open-access-imgOpen Access
Nanobased Platforms for Diagnosis and Treatment of COVID-19: From Benchtop to Bedside
Author(s) -
Elham Bidram,
Yasaman Esmaeili,
Abbas Amini,
Rossella Sartorius,
Franklin R. Tay,
Laleh Shariati,
Pooyan Makvandi
Publication year - 2021
Publication title -
acs biomaterials science and engineering
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.082
H-Index - 50
ISSN - 2373-9878
DOI - 10.1021/acsbiomaterials.1c00318
Subject(s) - covid-19 , intensive care medicine , coronavirus , virology , medicine , immunology , outbreak , disease , infectious disease (medical specialty) , pathology
Human respiratory viral infections are the leading cause of morbidity and mortality around the world. Among the various respiratory viruses, coronaviruses (e.g., SARS-CoV-2) have created the greatest challenge and most frightening health threat worldwide. Human coronaviruses typically infect the upper respiratory tract, causing illnesses that range from common cold-like symptoms to severe acute respiratory infections. Several promising vaccine formulations have become available since the beginning of 2021. Nevertheless, achievement of herd immunity is still far from being realized. Social distancing remains the only effective measure against SARS-CoV-2 infection. Nanobiotechnology enables the design of nanobiosensors. These nanomedical diagnostic devices have opened new vistas for early detection of viral infections. The present review outlines recent research on the effectiveness of nanoplatforms as diagnostic and antiviral tools against coronaviruses. The biological properties of coronavirus and infected host organs are discussed. The challenges and limitations encountered in combating SARS-CoV-2 are highlighted. Potential nanodevices such as nanosensors, nanobased vaccines, and smart nanomedicines are subsequently presented for combating current and future mutated versions of coronaviruses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here